The goal of Biomolecular Therapeutics is to develop drugs that specifically target medically-important biological macromolecules in a disease state, thereby altering their action in a manner that achieves a therapeutic benefit. Biomolecular Therapeutics encompasses a diverse array of disease states and targets and therefore impacts most of the research focus areas pursued at the IBBR and other research centers throughout the University System of Maryland (USM).
A major driver in Biomolecular Therapeutics is the Center for Biomolecular Therapeutics (CBT). The CBT is a USM-wide initiative, facilitated by a partnership between the University of Maryland-Baltimore and the University of Maryland at College Park at the IBBR, which is dedicated to the development of commercial diagnostic and therapeutic products that benefit human and environmental health. The CBT has investigators with the full range of scientific expertise required for the development of therapeutics. In particular, the CBT comprises seven sections: Genomics and Bioinformatics, Medicinal Chemistry, Target Validation and Screening, In vivo Biology and Drug Testing, Protein Production and Biophysics, Structural Biology, and Computer-aided Drug Design. The CBT leverages this expertise to collaborate with USM investigators and industry partners to investigate targets of both medical and commercial importance. Through this partnership, the CBT is developing a “discovery-to-commercialization” pipeline that couples state-of-the art science with business and regulatory expertise to accelerate the translation of important basic science discoveries to the marketplace.